
Barclays analyst Glen Santangelo raised the firm’s price target on Bausch Health (BHC) to $9 from $7 and keeps an Equal Weight rating on the shares following the Q3 report.
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BHC | Bausch Health Companies | 8.35 | 2.07 | 32.96% |
| Name | Price | % Change | |
|---|---|---|---|
| $8.35 | +32.96% |

Barclays analyst Glen Santangelo raised the firm’s price target on Bausch Health (BHC) to $9 from $7 and keeps an Equal Weight rating on the shares following the Q3 report.

Jefferies raised the firm’s price target on Bausch Health (BHC) to $8 from $6.50 and keeps a Hold rating on the shares. The firm notes the company reported the 14th

Reports Q3 revenue $2.94B, consensus $2.7B. “Bausch Health (BHC), excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth. We also

The company announced that its Board of Directors has authorized a $50M share repurchase program, with the primary objective of offsetting dilution associated with the anticipated vesting of management equity

Sees FY26 adjusted EBITDA $4.315B-$4.415B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More

Pre-earnings options volume in Bausch Health (BHC) is 1.4x normal with calls leading puts 15:2. Implied volatility suggests the market is anticipating a move near 8.1%, or 55c, after results

Bausch Health (BHC), Canada, a subsidiary of Bausch Health Companies, announced expanded public reimbursement for okedi 75 mg and 100 mg, with coverage now available for eligible patients, subject to

The major averages were mixed near noon as investors weigh rising oil prices and geopolitical risks against expectations for another strong corporate earnings season. Brent crude reached a roughly two-week

Bausch Health (BHC) Companies and its gastroenterology business, Salix Pharmaceuticals, announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based

Bausch + Lomb (BLCO) and its parent company, Bausch Health (BHC), announced that Bausch + Lomb Board of Directors Chairman Thomas Appio has been appointed interim chief executive officer, effective
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 24, 2027TBA | $3.12B | $1.35 | $2.73B | -0.04 | -3.68 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.